Capricor Therapeutics to Announce Q1 2024 Financial Results and Corporate Update on May 13

Capricor Therapeutics, a biotechnology firm listed on NASDAQ under the symbol CAPR, is preparing to announce its financial outcomes for the first quarter ending on March 31, 2024. This announcement will take place after the market closes on Monday, May 13, 2024. Subsequently, the company's management will host a webcast and conference call at 4:30 p.m. ET on the same day to discuss the results.

Participants can join the conference call using the toll-free number 1-888-886-7786 or the international number 1-416-764-8658, utilizing the Conference ID 01529679. Alternatively, participants can gain instant telephone access by clicking the Call me™ link. A webcast link will also be available, and a replay of the webcast will be accessible on the company's website after the live broadcast concludes.

Capricor Therapeutics is dedicated to the development of innovative cell and exosome-based therapies to transform the treatment landscape for rare diseases. Their lead product candidate, CAP-1002, is an allogeneic therapy derived from cardiac cells. This product has shown promising immunomodulatory, antifibrotic, and regenerative effects in both preclinical and clinical studies. It is currently in Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD).

In addition to CAP-1002, Capricor is advancing its exosome technology, leveraging its proprietary StealthX™ platform. This platform is in preclinical development for applications in vaccinology and the targeted delivery of oligonucleotides, proteins, and small molecule therapeutics. These efforts aim to address and potentially prevent a range of diseases.

Capricor has also formed a partnership with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of CAP-1002 for DMD in the United States and Japan, pending regulatory approval. CAP-1002 is currently classified as an Investigational New Drug and has not received approval for any indications. Similarly, none of Capricor’s exosome-based candidates have been approved for clinical investigation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!